Welcome to Richmond Pharmacology

Market-leading contract research organisation, specialising in Early Phase Trial Management

Watch our
video

Adaptive
Phase I, II & III

Taking your drug from
First-In-Human to Proof of Concept in less than nine months.

Learn
more

Bridging
Studies

Cost effective, time efficient and safe protocol design.

Bridging Studies

Thorough & Intensive QTc Studies

From advice by renowned experts to competent study conduct and ECG Analysis. All under one roof

TQT 
Studies

Patient Recruitment

Fast, efficient recruitment using our database of 250,000 active potential participants

Find out
more

UK's leading clinical research organisation

Since 2001, Richmond Pharmacology has conducted over 500 Early Phase Studies, delivering exceptional customer service, and exceeding the expectations of our sponsors. We have significant experience in running a range of patient trials, adding value to the studies by incorporating detailed analysis of the cardiovascular effects of drugs.

We are industry leaders in Adaptive Phase I and II studies, Thorough-QT, Japanese Bridging Studies and Patient Recruitment. Our services span consultancy and concept development through to final reporting.

As a sponsor, you will receive a personal and truly strategic experience and our knowledgeable staff will ensure your trial delivers meaningful results.

Our business ethos is unique:
Our business is sustainable, adaptive to change and is led by the same specialists who founded Richmond Pharmacology nineteen years ago. Our founders are involved in each clinical research trial, so you are assured of a personal service throughout.

We are committed to advancing science and improving patient safety. Our revenues are reinvested in the business and the newly developed, not-for-profit research organisation – Richmond Research Institute. The Institute was born from our partnership with St George’s University London and a mutual desire to expand academic research in key fields of cardiology, hepatology, clinical trial methodology and racial and sex differences in human physiology.

From initial contact to the completion of the study, our drug developers and investors find working with us enjoyable and rewarding.

What makes us special

Work with our experts

Conduct your trial in a cost effective and timely manner

Get in touch today

Latest news

Upcoming Event

The 41st Annual Scientific Meeting of the Japanese Society of Clinical Pharmacology and Therapeutics (JSCPT)

4 – 5 December 2020
The 41st Annual Scientific meeting focuses on international collaboration in the pursuit of drug discovery and drug development.
View event

Marking a milestone for gene editing

November 10, 2020
We are pleased to share that Richmond Pharmacology, in partnership with Intellia Therapeutics and the Royal Free Hospital, have treated the first patient in a landmark CRISPR/Cas9 clinical trial of NTLA-2001
Read more

Richmond Pharmacology is delighted to confirm partnership with Intellia Therapeutics

October 20, 2020
Phase I study of Intellia Therapeutic’s NTLA-2001 for the treatment of hereditary transthyretin amyloidosis with polyneuropathy (hATTR-PN)
Read more

Richmond Pharmacology supports ReViral with the development of Sisunatovir

September 9, 2020
ReViral has confirmed the FDA has granted Fast Track designation to Sisunatovir.
Read more